The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations

Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR), were the first molecularly targeted agents to become clinically available for the treatment of non-small cell lung cancer (NSCLC). During the course of their clinical development...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Okamoto, Isamu, Mitsudomi, Tetsuya, Nakagawa, Kazuhiko, Fukuoka, Masahiro
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2010
Assuntos:
Reviews
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3126025/
https://ncbi.nlm.nih.gov/pubmed/21789142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834010370698
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares